LUMINA is an Advanced Minimal Residual Disease Detection Platform for Lung Cancer Harnessing the Power of Multi-omics Biomarkers and AILOS ...

Oncologists want definitive guidance on whether patients with resectable NSCLC benefit from immunotherapy before and after ...

Aging brings two opposing trends in cancer risk: first, the risk climbs in our 60s and 70s, as decades of genetic mutations ...

BioAffinity Technologies' 2023 acquisition Precision Pathology Laboratory Services led to more than $9.4 million in 2024 ...

A noteworthy case study. What's next for a premenopausal 40-year-old woman in Syria with recurrent hormone receptor-positive ...

The FDA has approved a new drug called ensartinib for adults with a type of lung cancer called ALK-positive non-small-cell lung cancer (NSCLC).

AI-driven tools for prescreening patients, predicting responses and outcomes, and guiding patient therapy are maturing and entering the market.

Low lung cancer screening awareness in underserved communities is linked to barriers like education and healthcare access, ...

A new molecular imaging agent can accurately identify a crucial biomarker found among many different types of cancer. Precise ...